Gold Moves Lower; TransCode Therapeutics Shares Surge
Portfolio Pulse from Lisa Levin
U.S. stocks traded mixed with the Nasdaq Composite trading higher and the Dow trading down. TransCode Therapeutics shares surged 218% after announcing pre-clinical gliblastoma results. ESS Tech shares rose 24% after Honeywell International entered into a strategic collaboration with ESS Tech. Biophytis shares gained 54% after announcing a partnership agreement for the production of Sarconeos for severe forms of Covid-19. SCYNEXIS shares dropped 34% after recalling BREXAFEMME and halting clinical studies. Brainstorm Cell Therapeutics shares were down 33% after the FDA said there is insufficient evidence to support the company's ALS therapy. Morphic Holding shares fell 37% after BTIG downgraded the stock from Buy to Neutral.
September 25, 2023 | 6:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biophytis shares gained after announcing a partnership agreement for the production of Sarconeos for severe forms of Covid-19.
The announcement of a partnership for the production of a potential treatment for severe forms of Covid-19 is a positive signal for the company, which could lead to increased investor confidence and a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
ESS Tech shares rose after Honeywell International entered into a strategic collaboration with ESS Tech.
Strategic collaborations often lead to increased investor confidence and a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
TransCode Therapeutics shares surged after announcing pre-clinical gliblastoma results.
The announcement of positive pre-clinical results is a strong positive signal for the company, which could lead to increased investor confidence and a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Brainstorm Cell Therapeutics shares were down after the FDA said there is insufficient evidence to support the company's ALS therapy.
Negative comments from the FDA regarding a company's therapy is a negative signal for the company, which could lead to decreased investor confidence and a drop in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Morphic Holding shares fell after BTIG downgraded the stock from Buy to Neutral.
A downgrade from an analyst is a negative signal for the company, which could lead to decreased investor confidence and a drop in the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
SCYNEXIS shares dropped after recalling BREXAFEMME and halting clinical studies.
The recall of a product and the halting of clinical studies is a negative signal for the company, which could lead to decreased investor confidence and a drop in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100